Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YST-OVH
- Development stage
- Unknown
- Lead developer
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
YST-OVH is an oncolytic virus therapy based on a genetically modified Herpes Simplex Virus type 1 (HSV-1). Developed by the National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD) at Xiamen University, the virus is engineered to selectively infect, replicate within, and lyse malignant tumor cells while sparing normal healthy tissue. This selective replication leads to direct oncolysis, which releases tumor-associated antigens and danger-associated molecular patterns (DAMPs) into the tumor microenvironment. This process is intended to overcome local immunosuppression and stimulate a systemic, durable antitumor immune response. YST-OVH is currently being evaluated in Phase 1 clinical trials for the treatment of various malignant tumors.
- Other names
- HSV-1 oncolytic virusHSV1 oncolytic virusHSV 1 oncolytic virus
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on YST-OVH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YST-OVH.